Shandong Xinhua Pharmaceutical Gets China Nod for Eszolam Marketing License Transfer

MT Newswires Live

04/15

Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) has obtained approval for a change in the marketing licence holder of its Eszolam tablets from China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.

The company had, in November 2022, entered into an agreement with Guangxi Dahai Sunshine Pharmaceutical, which agreed to transfer its Marketing Authorization Holder (MAH) status to the former for Eszolam.

The drug is mainly used for anti-anxiety, insomnia or tension, fear, antiepileptics, and anti-convulsions.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2527945512"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527945512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527945512?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-15 15:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527945512","market":"fut","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical Gets China Nod for Eszolam Marketing License Transfer","media":"MT Newswires Live","content":"<html><body><p> Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) has obtained approval for a change in the marketing licence holder of its Eszolam tablets from China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.</p><p>The company had, in November 2022, entered into an agreement with Guangxi Dahai Sunshine Pharmaceutical, which agreed to transfer its Marketing Authorization Holder (MAH) status to the former for Eszolam.</p><p>The drug is mainly used for anti-anxiety, insomnia or tension, fear, antiepileptics, and anti-convulsions.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical Gets China Nod for Eszolam Marketing License Transfer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical Gets China Nod for Eszolam Marketing License Transfer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-04-15 15:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) has obtained approval for a change in the marketing licence holder of its Eszolam tablets from China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.</p><p>The company had, in November 2022, entered into an agreement with Guangxi Dahai Sunshine Pharmaceutical, which agreed to transfer its Marketing Authorization Holder (MAH) status to the former for Eszolam.</p><p>The drug is mainly used for anti-anxiety, insomnia or tension, fear, antiepileptics, and anti-convulsions.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527945512","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527945512","pubTimestamp":1744701700,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shandong Xinhua Pharmaceutical  has obtained approval for a change in the marketing licence holder of its Eszolam tablets from China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.The company had, in November 2022, entered into an agreement with Guangxi Dahai Sunshine Pharmaceutical, which agreed to transfer its Marketing Authorization Holder  status to the former for Eszolam.The drug is mainly used for anti-anxiety, insomnia or tension, fear, antiepileptics, and anti-convulsions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","000756":"新华制药","BK7095":"多种金属与采矿","BK0239":"医药制造","BK0164":"国企混改","00719":"山东新华制药股份","MAH.AU":"MACMAHON HOLDINGS LIMITED","BK1515":"抗疫概念"},"translate_title":"山东新华制药艾司唑仑上市许可转让获得中国认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAH.AU":1,"00719":0.9,"000756":0.9},"content_text":"Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) has obtained approval for a change in the marketing licence holder of its Eszolam tablets from China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.The company had, in November 2022, entered into an agreement with Guangxi Dahai Sunshine Pharmaceutical, which agreed to transfer its Marketing Authorization Holder (MAH) status to the former for Eszolam.The drug is mainly used for anti-anxiety, insomnia or tension, fear, antiepileptics, and anti-convulsions.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}